PriceTargets.com logo

Processa Pharmaceuticals - PCSA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.00
  • Forecasted Upside: 627.40%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.55 As of 05/26/2023 09:47 PM ET
▼ -0.0999 (-15.37%)

This chart shows the closing price for PCSA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Processa Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PCSA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PCSA

Analyst Price Target is $4.00
▲ +627.40% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Processa Pharmaceuticals in the last 3 months. The average price target is $4.00, with a high forecast of $5.00 and a low forecast of $3.00. The average price target represents a 627.40% upside from the last price of $0.55.

This chart shows the closing price for PCSA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Processa Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/2/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/31/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/29/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/28/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2023BenchmarkLower TargetSpeculative Buy$9.00 ➝ $4.00Low
4/3/2023OppenheimerLower TargetOutperform$5.00 ➝ $3.00Low
1/12/2023Maxim GroupLower TargetBuy$9.00 ➝ $5.00Low
5/13/2022BenchmarkLower Target$15.00 ➝ $9.00High
4/19/2022Maxim GroupInitiated CoverageBuyMedium
11/5/2021OppenheimerBoost TargetOutperform$20.00 ➝ $22.00High
8/2/2021OppenheimerInitiated CoverageOutperform$20.00High
12/8/2020BenchmarkInitiated CoverageBuyHigh
10/28/2020Craig HallumInitiated CoverageBuyLow
(Data available from 5/29/2018 forward)

News Sentiment Rating

-0.78 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/28/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/30/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
4/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/29/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Processa Pharmaceuticals logo
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Hanover, MD.
Read More

Today's Range

Now: $0.55
Low: $0.48
High: $0.66

50 Day Range

MA: $0.56
Low: $0.43
High: $0.72

52 Week Range

Now: $0.55
Low: $0.36
High: $3.83

Volume

114,300 shs

Average Volume

203,565 shs

Market Capitalization

$13.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.16

Frequently Asked Questions

What sell-side analysts currently cover shares of Processa Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Processa Pharmaceuticals in the last year: Benchmark Co., Maxim Group, and Oppenheimer Holdings Inc..
View the latest analyst ratings for PCSA.

What is the current price target for Processa Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Processa Pharmaceuticals in the last year. Their average twelve-month price target is $4.00, suggesting a possible upside of 627.4%. Maxim Group has the highest price target set, predicting PCSA will reach $5.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $3.00 for Processa Pharmaceuticals in the next year.
View the latest price targets for PCSA.

What is the current consensus analyst rating for Processa Pharmaceuticals?

Processa Pharmaceuticals currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PCSA will outperform the market and that investors should add to their positions of Processa Pharmaceuticals.
View the latest ratings for PCSA.

What other companies compete with Processa Pharmaceuticals?

Other companies that are similar to Processa Pharmaceuticals include Chembio Diagnostics, NeuroBo Pharmaceuticals, Indaptus Therapeutics, Evelo Biosciences and Tonix Pharmaceuticals. Learn More about companies similar to Processa Pharmaceuticals.

How do I contact Processa Pharmaceuticals' investor relations team?

Processa Pharmaceuticals' physical mailing address is 7380 COCA COLA DRIVE SUITE 106, HANOVER MD, 21076. The company's listed phone number is (443) 776-3133 and its investor relations email address is [email protected]. The official website for Processa Pharmaceuticals is www.processapharmaceuticals.com. Learn More about contacing Processa Pharmaceuticals investor relations.